Neurofilament Light Chain (NfL), Plasma
The Neurofilament Light Chain (NfL), Plasma test measures a structural axonal protein released during neuronal injury, providing a sensitive, non-specific marker of CNS damage. It is used to monitor multiple sclerosis activity and treatment response, quantify axonal loss in neurodegenerative disease, assess traumatic brain injury severity, and guide therapeutic decisions, with interpretation…
1
Biomarkers
Blood (plasma)
Sample
7–10 business days
Turnaround
No
Fasting
What is the Plasma NfL test?
The Neurofilament Light Chain (NfL), Plasma test quantifies a structural axonal protein released during neuronal injury, offering a blood-based window into central nervous system damage. It is ordered when practitioners need an objective, quantitative marker of disease activity or axonal loss in conditions ranging from inflammatory demyelination to neurodegeneration and neurotrauma. Plasma NfL does not diagnose a specific disorder — the pattern of clinical presentation, imaging, and other fluid or genetic markers supplies that — but it answers whether active axonal injury is occurring and whether it is responding to treatment. Serial measurement over months captures trajectory, and in clinical trials NfL is increasingly used as a surrogate endpoint. The test's appeal lies in accessibility: it replaces or complements cerebrospinal fluid sampling, and contemporary ultrasensitive immunoassays (single-molecule array, electrochemiluminescence) deliver clinically useful sensitivity from a peripheral blood draw.
What does the Plasma NfL test measure?
Neurofilament light chain is a structural protein of the neuronal cytoskeleton, expressed exclusively in axons. Following axonal injury or degeneration — whether from trauma, inflammation, ischaemia, or neurodegenerative processes — NfL is released into the cerebrospinal fluid and diffuses into blood. Its plasma concentration tracks axonal damage burden across diverse neurological conditions, and because elimination is primarily renal, levels rise modestly with age and impaired kidney function. The protein's half-life in blood is on the order of a few weeks, so plasma NfL integrates recent axonal loss rather than reflecting moment-to-moment fluctuation.
Plasma NfL has emerged as a fluid biomarker of active neuroaxonal injury. It is non-specific — elevated in multiple sclerosis, Alzheimer disease, frontotemporal dementia, Parkinson disease, traumatic brain injury, and cerebrovascular disease — but this breadth makes it a sensitive screening and monitoring tool. In multiple sclerosis it correlates with relapse activity, MRI lesion burden, and treatment response; in neurodegenerative disease it tracks disease stage and progression rate. Practitioners use NfL to detect subclinical disease activity, guide escalation of disease-modifying therapy, and monitor intervention efficacy, interpreted always within the clinical and imaging context.
Why is the Plasma NfL test ordered?
- Monitoring of multiple sclerosis activity and treatment response, where rising NfL signals breakthrough inflammation or inadequate disease control
- Evaluation of suspected or early neurodegenerative disease (Alzheimer disease, frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson disease) to quantify axonal loss and establish a baseline for progression
- Assessment of traumatic brain injury severity and recovery, where NfL correlates with imaging findings and functional outcome
- Investigation of unexplained cognitive decline or motor symptoms, when the clinical picture is atypical and an objective measure of CNS injury supports diagnostic workup
- Serial follow-up of patients on disease-modifying therapy for MS or neurodegenerative conditions, to detect subclinical activity and inform escalation or switching decisions
- Research and trial settings, where NfL serves as a pharmacodynamic biomarker of neuronal protection or treatment effect
- Baseline and post-intervention measurement in cerebrovascular disease or CNS infection, when quantifying injury burden aids prognostication
Sample collection and turnaround
Sample type
Blood (plasma)
Fasting required
No
Collection method
Venipuncture at patient service centre
Turnaround
7–10 business days
Collection notes
Phlebotomy via Quest. EDTA or heparin plasma; sample should be separated promptly and frozen if not analysed immediately. Avoid haemolysis. No special dietary preparation is required.
Specimen requirements
Minimum 0.5 mL EDTA or heparin plasma. Separate within 2 hours of collection; freeze at –80°C if storage exceeds 24 hours. Note the assay platform (typically Simoa or electrochemiluminescence) for serial comparability.
What can affect Plasma NfL results?
Plasma NfL rises steadily with age, reflecting cumulative subclinical neuronal loss and possibly age-related changes in clearance. Age-adjusted reference ranges or Z-scores are essential for interpretation.
NfL is cleared through the kidneys, so reduced glomerular filtration raises plasma concentration independently of neurological injury. Correlate with eGFR or creatinine when interpreting elevated results.
Higher BMI is associated with lower plasma NfL, possibly through increased volume of distribution. The effect is modest but measurable in large cohorts.
Different immunoassay methods (Simoa, Ella, Elecsys) yield slightly different absolute values, and haemolysis or delayed plasma separation can alter results. Serial samples should use the same platform and standardised handling.
Severe systemic inflammation, hypoxia, or major surgery can transiently raise NfL, likely through secondary CNS effects or peripheral nerve involvement. Interpret acute elevations in clinical context.
NfL is released from damaged peripheral as well as central axons, so chemotherapy-induced neuropathy, Guillain-Barré syndrome, or severe diabetic neuropathy can raise plasma levels in the absence of CNS disease.
What do Plasma NfL results mean?
Elevated
Active axonal injury: relapsing or progressive multiple sclerosis, neurodegenerative disease (Alzheimer, frontotemporal dementia, ALS, Parkinson), traumatic brain injury, cerebrovascular events, CNS infection, or severe peripheral neuropathy. Very high values (several hundred pg/mL) suggest acute, extensive damage — seen in TBI, status epilepticus, or fulminant demyelination. Modest chronic elevation is typical of slowly progressive neurodegeneration.
Normal
An age-appropriate NfL supports absence of active neuroaxonal damage at the time of sampling but does not exclude a neurological diagnosis — many stable, treated, or early-stage conditions present with normal values. Trending over time is more informative than a single normal result.
Reduced
Low NfL has no established clinical significance and generally reflects absence of significant active axonal injury. It does not exclude stable or chronic disease without ongoing axonal loss.
Note: NfL is sensitive but non-specific; clinical context, imaging, and other biomarkers are essential. Because values rise with age and renal impairment, interpret against age-stratified norms and eGFR. Serial measurements, ideally on the same platform, are more useful than cross-sectional snapshots. A rising trend signals disease progression or treatment failure even when absolute values remain within reference limits.
Frequently asked questions
NfL is a structural protein of the neuronal cytoskeleton released into blood when axons are injured or degenerate. Plasma NfL reflects the burden of active neuroaxonal damage across diverse neurological conditions.
How to access the Plasma NfL test
The Plasma NfL reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: October 7, 2026
Last reviewed: October 7, 2026
- Khalil M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. (2018)
- Barro C, et al. Blood neurofilament light chain as a dynamic biomarker of neurological disease. Expert Rev Mol Diagn. (2020)
- Gaetani L, et al. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. (2019)
- Disanto G, et al. Serum neurofilament light chain: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol. (2017)
- Bridel C, et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol. (2019)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.